Kyle Hoellger
Apr 22, 2014
•
Featured
Valeant Offers to Buy Allergan
Canadian based Valeant Pharmaceuticals has made an offer to buy Allergan for $45.7B in cash and stock. Investors in the Botox-producing Allergan would receive $48.30 in cash and 0.83% in Valeant stock for each share their currently own under the terms of the proposed deal.